In this pilot study we examined the effect of sera from a proprietary hyperimmune plasma product (Equiplas) on the activity of TNF: in an in vitro L929 cell bioassay. In brief, we report observations from 2 accessions of sera. Accession 1 describes the antiTNF: activity of 3 hyperimmune sera and an untreated serum sample that were provided blind to the study. Accession 2 reports a comparison of antiTNFalpha activity found in 3 paired hyperimmune sera collected following a multiple endotoxin vaccination regimen
